CDKN2A and ovarian cancer: For this aim, they screened 40 ovarian cancer cell lines for their sensitivity to palbociclib and identified the so-called Rb1-proficient cell lines, with low p16INK4A and CCNE1 expression, as the most responsive to CDK4/6i.